Vaccine Development

Our clinical research unit is located at the Department of Infectious Diseases’ outpatient clinic and ward. The unit performs clinical research projects and trials of new drugs in the specialty of Infectious Diseases.

Denmark is a very attractive country when international pharmaceutical companies are to test new treatment therapies and drugs. The main reason for this is, that Denmark has some of the world’s best national health registers and databases. All hospitals and general practitioners in Denmark collect statistical data about Danish diseases and health, which provides unique opportunities to develop better therapies for the patients. Because of the Danish registers and health data and a generally high level of education the Danish research is world known to be of very high quality.

Our clinical research unit is specialized in carrying out research projects on the basis of Danish health registers. If a new drug is to be tested on a specific target group, we can make a very precise selection and find the group of potential participants with the exact age, background and medical history, the experiment demands. In recent years, our research unit has implemented major vaccine trials of new herpes, meningitis and hepatitis vaccines with a large number of healthy patients. Additionally, the unit continuously completes clinical trials in HIV and other diseases in the specialty of Infectious Diseases.

Focus on patient safety and quality

All employees with association to the clinical research unit have attended courses in GCP (Good Clinical Practice), which is an international ethical and scientific quialty standard of the implementation of drug trials involving human beings. GCP helps ensure the test subjects’ safety, rights and welfare are protected. By following GCP it is also ensured that the collected data are valid, complete and well documented. Moreover, GCP guarantees independence between the public health services that performs the test, and the private pharmaceutical industry, which sponsors the drug.

In Denmark the comprehensive health registers also serves as an extra security for the persons involved in the drug trials, because it is possible to identify participants quickly, even many years after the study is done, if there for example should occur any unforeseen side effects.